Physician profile
Jason Skiwski
NPI 1992715130
$2,094.44
in general payments reported to CMS, 2019-2025
27 companies · $95.76 in 2025
The $95.76 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $268 · 2021: $374 · 2022: $715 · 2023: $510 · 2024: $17.56 · 2025: $95.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $333.19 | 2020-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $244.92 | 2019-2022 | |
| Corium, LLC | $205.19 | 2021-2025 | Azstarys |
| Tris Pharma INC | $155.08 | 2019-2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $139.78 | 2021-2023 | Qelbree |
| Cranial Technologies, INC | $121.20 | 2019-2023 | Doc Band |
| Abbott Laboratories | $117.63 | 2021-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $97.06 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $89.07 | 2021-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $71.96 | 2023 | Korlym |
| Pfizer INC. | $69.52 | 2020-2023 | |
| Neos Therapeutics, LP | $61.46 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $58.48 | 2020-2025 | Gardasil 9, Enflonsia, Vaxelis |
| Lilly USA, LLC | $54.62 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $42.56 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $41.30 | 2025 | Jornay Pm |
| Novo Nordisk INC | $32.32 | 2023 | Ozempic, Rybelsus, Wegovy |
| Genzyme Corporation | $23.51 | 2022 | |
| Seqirus USA INC | $18.83 | 2025 | Flucelvax |
| Glaxosmithkline, LLC. | $17.22 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.94 | 2019 | |
| Qol Medical, LLC | $15.57 | 2023 | Sucraid |
| Shire North American Group INC | $15.01 | 2019 | |
| Eusa Pharma (US) LLC | $13.92 | 2022 | |
| Recordati_rare_diseases_inc. | $13.92 | 2022 | |
| Sanofi Pasteur INC. | $12.27 | 2022 | |
| Adlon Therapeutics L.P. | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Skiwski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.